I-Mab Announces Financial Results for the Full Year Ended December 31, 2019, and Provides Corporate Update

NEXT STORY
FDA Accepts Investigational New Drug Application for CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate Developed Under Collaboration with Intellia Therapeutics
PREV STORY
BioNTech Announces Full Year 2019 Financial Results and Corporate Update
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

MediWound Reports Second Quarter Financial Results

author_avatar
NASDAQ Market News

UroGen Pharma Reports Second Quarter 2018 Financial Results and Recent Corporate Developments  

Plan to Initiate Q4 2018 Rolling New Drug Application (NDA) Submission to the U.S. ...

author_avatar
NASDAQ Market News

Global $19.4 Bn Gene Expression Markets to 2028 – Rise in Investments for the Development of Alternative Drug Discovery Approaches

author_avatar
NASDAQ Market News